CJC-1295 Research Guide: DAC Chemistry, GHRH Signaling, and Evidence Limits
A direct-literature review of DAC CJC-1295, albumin bioconjugation, early human GH-axis biomarkers, and the no-DAC naming problem.
DAC status is part of the molecule, not a minor label
CJC-1295 was developed as a modified GHRH(1-29) analog bearing a Drug Affinity Complex reactive group. The DAC chemistry forms a covalent conjugate with circulating albumin, materially changing persistence and making it central to the identity studied in the foundational papers.
Early human trials measured pharmacokinetics, GH, and IGF-I. A small follow-up study explored serum-protein profiles. These biomarkers establish pharmacologic activity under controlled conditions but do not prove body-composition, recovery, sleep, performance, or anti-aging outcomes.
Online products called CJC-1295 without DAC or modified GRF(1-29) are structurally different. They cannot inherit the DAC CJC-1295 papers merely because sellers use a similar name.
What researchers are trying to understand
What does DAC mean in CJC-1295?
Drug Affinity Complex refers to a reactive modification designed to conjugate the peptide to albumin. It changes the studied molecule's disposition.
Is CJC-1295 without DAC the same compound?
No. A no-DAC or modified-GRF material lacks the defining albumin-binding construct from the cited CJC-1295 papers.
What did the human studies establish?
They characterized exposure and GH-axis biomarkers. They did not establish durable body-composition, recovery, sleep, or anti-aging outcomes.
Notable studies, in plain English
The studies below are separated by model and design so that early laboratory signals are not confused with evidence from people.
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
- Model
- Animal and in vitro
- Design
- Rat pituitary-cell and in vivo rat experiments characterizing albumin bioconjugation and GHRH-receptor pharmacology.
What the paper reported: The study identified CJC-1295 as a DAC-containing albumin-binding GHRH analog with prolonged preclinical activity.
Important limit: Preclinical pharmacology cannot establish human benefit or validate vendor products.
Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
- Model
- Human
- Design
- Two randomized, placebo-controlled, double-blind, ascending-exposure studies in healthy adults.
What the paper reported: The studies characterized CJC-1295 pharmacokinetics and prolonged GH and IGF-I biomarker responses.
Important limit: Early-phase, short-term, biomarker-focused research does not prove performance or health outcomes.
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
- Model
- Human
- Design
- Exploratory serum-proteomic analysis in 11 healthy men exposed to CJC-1295.
What the paper reported: The study reported changes in selected serum proteins during controlled GH-axis stimulation.
Important limit: Very small exploratory dataset with no validated clinical outcome and substantial multiple-marker interpretation risk.
What the evidence does—and does not—establish
The direct peer-reviewed literature is unusually small: one foundational preclinical paper, early human biomarker studies, and a small exploratory proteomic analysis.
GH and IGF-I responses are surrogate pharmacodynamic measures. They do not establish a durable change in muscle, fat, sleep, recovery, aging, or quality of life.
DAC status, sequence substitutions, reactive group, salt form, and mass are identity-critical. A no-DAC material cannot be represented by the DAC literature.
- Published CJC-1295 includes DAC albumin-binding chemistry.
- The direct evidence base contains only a few papers.
- Human studies focused on pharmacokinetics and biomarkers.
- CJC-1295 no DAC is a different structural proposition.
- A paper cannot authenticate a seller's lot.
Where to buy CJC-1295 for laboratory research in the USA
The product page should explicitly state DAC or no-DAC status, the complete modified sequence, reactive group if present, salt form, theoretical and observed mass, quantity, and lot number. Ambiguous CJC naming prevents accurate literature matching.
Review the lot-specific COA, chromatogram, test date, storage documentation, shipping origin, and support contact. A supplier should not cite DAC studies beside a no-DAC listing without a prominent non-equivalence statement.
Searches such as “where to buy CJC-1295,” “buy CJC-1295 USA,” and “USA peptides” should be treated as laboratory-sourcing questions. Compare U.S. research suppliers by lot traceability, identity testing, quantitative-content information, analytical methods, and stated research-use restrictions—not by implied human outcomes.
CJC-1295 research FAQ
Is CJC-1295 the same as modified GRF(1-29)?
The published DAC CJC-1295 construct is not the same as a no-DAC or modified-GRF material.
Why does albumin binding matter?
It changes the molecule's disposition and was a core design feature of the cited CJC-1295 research.
Do higher GH or IGF-I biomarkers prove body-composition benefits?
No. Biomarker changes are not proof of durable clinical or performance outcomes.
How much direct CJC-1295 literature exists?
The direct set mapped here is small: a foundational preclinical paper, early human pharmacology trials, and a small proteomic study.
What should a CJC-1295 COA identify?
It should identify DAC status, modified sequence, observed mass, chromatographic purity, lot number, and test date.
Primary references
References link to the original journal record or publisher page. Inclusion is not an endorsement of a product or a clinical conclusion.
- Jette L et al. Endocrinology. 2005. PMID 15817669. DOI 10.1210/en.2004-1286.
- Teichman SL et al. Journal of Clinical Endocrinology & Metabolism. 2006;91:799-805. PMID 16352683. DOI 10.1210/jc.2005-1536.
- Sackmann-Sala L et al. Growth Hormone & IGF Research. 2009. PMID 19386527. DOI 10.1016/j.ghir.2009.03.001.